Expert Blog | Beta Cells in Diabetes

Expert BlogBlog RSS

About the Blog

This forum allows a wide variety of leading researchers, endocrinologists, and primary care providers to expand informally on emerging research, case studies, and resources related to beta cells in diabetes, as well providing an opportunity for you to discuss and debate these issues.

Posts by Topic

Posts by Author

Considering CAD Risk Factors in Treatment Decisions
Posted June 12, 2013 by Doron Schneider, MD, FACP

Tags: beta cell pathophysiology, glycemic control, lifestyle changes, weight

Doron Schneider, MD and Jack Leahy, MD discuss the importance of patient BMI and other risk factors for coronary artery disease when weighing treatment options.
- Continue Reading
- 0 Comments
Doron Schneider, MD, FACP

General Internist

Biography
Treatment Options for a Young, Newly Diagnosed Patient with a High BMI
Posted May 29, 2013 by John L. Leahy, MD

Tags: DPP-4 inhibitors, GLP-1 agonists, glycemic control, insulin therapy, lifestyle changes, metformin, prediabetes, sulfonylureas (SUs), thiazolidinediones (TZDs), weight

Dr. Jack Leahy, endocrinologist and general internist, Dr. Doron Schneider, weigh different initial treatment options presented by leading endocrinologists Silvio Inzucchi, MD, Alan J. Garber, MD and Laurence Kennedy, MD
- Continue Reading
- 1 Comment
John L. Leahy, MD

Endocrinologist

Biography
A Newly Diagnosed T2DM Patient with a High BMI: Primary Care Perspective
Posted May 16, 2013 by Jay Shubrook, DO, FACOFP, FAAFP

Case 6—A Newly Diagnosed Patient with a High BMI—is a very common scenario for the primary care physician. There are a number of issues worth highlighting before I outline my suggestions for treatment.
- Continue Reading
- 4 Comments
Jay Shubrook, DO, FACOFP, FAAFP

Endocrinologist and Family Physician

Biography
How the Affordable Care Act is Changing the Landscape of Diabetes
Posted March 19, 2013 by Doron Schneider, MD, FACP

Tags: beta cell pathophysiology

It is certainly a new world. As a result of healthcare reform the landscape of diabetes care has forever been altered. The practicing clinician, patient and healthcare administrators all need to have a firm grasp of these new realities if they wish to prosper now and into the future. In this blog I intend to provide a high level overview of the different ways that diabetes care is affected in this brave new world.
- Continue Reading
- 0 Comments
Doron Schneider, MD, FACP

General Internist

Biography
A Partnership to Optimize Patient Health in Diabetes
Posted March 18, 2013 by Jay Shubrook, DO, FACOFP, FAAFP

Tags: beta cell pathophysiology, lifestyle changes, metformin

There is almost no other disease as pervasive as type 2 diabetes, a disease that has touched almost every family in America. Although there was a time when we had limited management tools, we now have ten classes of medications plus many kinds of insulin available as options.
- Continue Reading
- 0 Comments
Jay Shubrook, DO, FACOFP, FAAFP

Endocrinologist and Family Physician

Biography
Here We Go Again: Another New Therapy For Type 2 Diabetes
Posted January 17, 2013 by John L. Leahy, MD

Tags: SGLT-2 inhibitors, DPP-4 inhibitors, insulin therapy

(Full disclosure – I am an Advisor to Janssen pharmaceuticals that makes canagliflozin)

An FDA advisory panel last week reviewed canagliflozin, with the majority recommending approval.
- Continue Reading
- 2 Comments
John L. Leahy, MD

Endocrinologist

Biography
Who is the Right Patient for SGLT-2 Inhibitors?
Posted January 17, 2013 by Irl B. Hirsch, MD

Tags: SGLT-2 inhibitors, DPP-4 inhibitors, GLP-1 agonists, insulin therapy, thiazolidinediones (TZDs)

Dr. Leahy’s comments are right-on target.
- Continue Reading
- 0 Comments
Irl B. Hirsch, MD

Endocrinologist

Biography
Challenges of Accelerating Treatment to Get to Goal
Posted September 6, 2012 by Doron Schneider, MD, FACP

Tags: insulin therapy

Dr. Doron Schneider, general internist, and Dr. Jack Leahy, endocrinologist, discuss intensifying therapy on a patient who is on two agents with A1C greater than 8.5.

Listen to the podcast or read the transcript
- 1 Comment
Doron Schneider, MD, FACP

General Internist

Biography
The Evolving Role of the Endocrinologist and Primary Care Doctor in Establishing Goals of Care
Posted August 23, 2012 by John L. Leahy, MD

Tags: glycemic control, lifestyle changes, weight

Listen to the Podcast and/or read the transcript.
- 1 Comment
John L. Leahy, MD

Endocrinologist

Biography
Podcast: A Discussion About 2012 ADA/EASD Position Statement
Posted August 2, 2012 by Doron Schneider, MD, FACP

Tags: beta cell pathophysiology, DPP-4 inhibitors, GLP-1 agonists, glycemic control, insulin therapy, lifestyle changes, metformin, prediabetes, sulfonylureas (SUs), thiazolidinediones (TZDs), weight

Listen to the Podcast and/or read the transcript.
- 0 Comments
Doron Schneider, MD, FACP

General Internist

Biography

Betacell

A resource for physicians established by the Endocrine Society

Text Size:

Expert BlogBlog RSS

About the Blog

Posts by Topic

Posts by Author

Considering CAD Risk Factors in Treatment Decisions

Treatment Options for a Young, Newly Diagnosed Patient with a High BMI

A Newly Diagnosed T2DM Patient with a High BMI: Primary Care Perspective

How the Affordable Care Act is Changing the Landscape of Diabetes

A Partnership to Optimize Patient Health in Diabetes

Here We Go Again: Another New Therapy For Type 2 Diabetes

Who is the Right Patient for SGLT-2 Inhibitors?

Challenges of Accelerating Treatment to Get to Goal

The Evolving Role of the Endocrinologist and Primary Care Doctor in Establishing Goals of Care

Podcast: A Discussion About 2012 ADA/EASD Position Statement